Johnson & Johnson (NYSE:JNJ) Trading 3.6% Higher – Still a Buy?

Johnson & Johnson (NYSE:JNJ) traded up 3.6% on Tuesday . The company traded as high as $239.80 and last traded at $239.66. Approximately 11,694,858 shares changed hands during mid-day trading, an increase of 39% from the average session volume of 8,389,777 shares. The stock had previously closed at $231.29.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced it will spend more than $1 billion to expand its Vision manufacturing, packaging, and distribution operations in Jacksonville, Florida, supporting domestic ACUVUE contact lens production and reinforcing its broader $55 billion U.S. investment plan. Johnson & Johnson (JNJ) Is Spending More Than $1 Billion On Jacksonville Vision Expansion
• Positive Sentiment: Analysts and market commentators published upbeat takes on J&J, including a piece arguing the stock is an attractive portfolio holding for defensive, dividend-focused investors. Johnson & Johnson: An Excellent Portfolio Option To Barbell AI, Initiate Buy Rating
• Positive Sentiment: Another article highlighted how J&J is using U.S. manufacturing investment to strengthen its Vision business, reinforcing confidence in the company’s long-term growth strategy. How Johnson & Johnson (JNJ) Is Using U.S. Manufacturing Investment to Strengthen Its Vision Business
• Neutral Sentiment: There were also broader healthcare industry stories about drugmakers banding together to address employment challenges, but these did not appear to directly affect J&J’s fundamentals. BIO 2026: Drug manufacturers band together to tackle employment challenges

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Sanford C. Bernstein lifted their price objective on shares of Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a report on Wednesday, April 15th. Leerink Partners upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target on the stock in a research report on Wednesday, May 13th. Johnson Rice raised shares of Johnson & Johnson from a “hold” rating to an “outperform” rating in a report on Wednesday, May 13th. Barclays boosted their price objective on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 15th. Finally, Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a report on Wednesday, April 15th. Twenty research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $253.04.

Johnson & Johnson Stock Up 3.6%

The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The firm has a market capitalization of $576.91 billion, a P/E ratio of 27.71, a PEG ratio of 2.24 and a beta of 0.26. The firm’s fifty day moving average price is $230.41 and its 200-day moving average price is $228.43.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion for the quarter, compared to analysts’ expectations of $23.60 billion. During the same period in the previous year, the business earned $2.77 earnings per share. Johnson & Johnson’s revenue for the quarter was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were issued a dividend of $1.34 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date was Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 61.97%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

A number of institutional investors have recently bought and sold shares of the business. Greenberg Financial Group acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth about $954,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Johnson & Johnson by 4.3% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,030,835 shares of the company’s stock valued at $932,835,000 after purchasing an additional 208,765 shares during the last quarter. World Investment Advisors increased its holdings in Johnson & Johnson by 19.6% during the 4th quarter. World Investment Advisors now owns 161,343 shares of the company’s stock worth $33,390,000 after purchasing an additional 26,450 shares in the last quarter. JT Stratford LLC raised its stake in shares of Johnson & Johnson by 7.6% in the third quarter. JT Stratford LLC now owns 59,577 shares of the company’s stock worth $11,047,000 after purchasing an additional 4,216 shares during the last quarter. Finally, Coldstream Capital Management Inc. lifted its holdings in shares of Johnson & Johnson by 9.8% in the third quarter. Coldstream Capital Management Inc. now owns 95,662 shares of the company’s stock valued at $17,738,000 after purchasing an additional 8,533 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.